Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel small interfering RNA cotargeting strategy as treatment for colorectal cancer.

Surgery - 1 Aug 2012

Valentino Joseph D, Elliott Victoria A, Zaytseva Yekaterina Y, Rychahou Piotr G, Mustain W Conan, Wang Chi, Gao Tianyan, Evers B Mark

Abstract excerpt

BACKGROUND: RNA interference has the potential to be more selective than small molecule inhibitors and can be used to target proteins, such as Ras, that are currently undruggable. The purpose of our study was to determine the optimal cotargeting strategy of the commonly mutated PI3K/AKT/mTOR and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Carcinoma
Share to Class I Phosphatidylinositol 3-Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fluorouracil

Share to HCT116 Cells

Share to Phosphatidylinositol 3-Kinases

Share to ras Proteins

Share to RNA, Small Interfering

Source

Open in PubMed Open full text

Identifiers

PMID: 22828149
DOI: 10.1016/j.surg.2012.05.006
PMCID: PMC3555567

Genes

KRAS
DLD

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-22828149-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel small interfering RNA cotargeting strategy as treatment for colorectal cancer.PMID 22828149Read ↗

Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.Semantic proximity Read ↗

CRISPR screens identify a novel combination treatment targeting BCL-XL and WNT signaling for KRAS/BRAF-mutated colorectal cancers.Semantic proximity Read ↗

Targeted Molecular Therapy of the PI3K PathwaySemantic proximity Read ↗

Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells.Semantic proximity Read ↗

Selective Eradication of Colon Cancer Cells Harboring PI3K and/or MAPK Pathway Mutations in 3D Culture by Combined PI3K/AKT/mTOR Pathway and MEK Inhibition.Semantic proximity Read ↗

MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.Semantic proximity Read ↗

Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.Semantic proximity Read ↗

Focused screening reveals functional effects of microRNAs differentially expressed in colorectal cancerSemantic proximity Read ↗

Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA.Semantic proximity Read ↗

The association of TP53 mutations with the resistance of colorectal carcinoma to the insulin-like growth factor-1 receptor inhibitor picropodophyllin.Semantic proximity Read ↗

The Combined Anti-Tumor Effects of 5-Fluorouracil and Neurokinin Receptor Inhibitor, Aprepitant, against Colorectal Cancer: In vitro and In vivo StudySemantic proximity Read ↗

Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.